Nancy Danielle Ebelt, Ph.D.

[email protected]
626-256-4673
Nancy Danielle Ebelt, Ph.D.
Postdoctoral Fellow, Department of Immuno-Oncology
Research Area
  • Mechanisms of Resistance to Molecularly-targeted Therapies
  • Roles of Growth Factor Signaling in Solid Tumor Progression
Research Teams
Immuno-Oncology
Danielle completed her doctorate in cell and molecular biology at the University of Texas at Austin in 2015 having studied mechanisms of efficacy and resistance to small molecule kinase inhibitors in breast cancer. She joined the Beckman Research Institute at the City of Hope in 2016 as a post-doctoral fellow to receive training in the field of cancer immunotherapy. Her current research utilizes cell culture, immunohistochemistry, immunoblot, FACS, microscopy and quantitative PCR on models of human cancer in mice to explore the use of Salmonella as a vector with which to deliver therapeutic DNA sequences or antigens to tumor cells or cells of the immune system.

Location

Education & Experience

Degrees

  • 2015, The University of Texas at Austin, Institute for Cellular and Molecular Biology, Austin, TX, Ph.D., Cell and Molecular Biology

  • 2007, Texas A&M University, College of Agriculture and Life Sciences, College Station, TX, B.S., Genetics

Professional Experience

  • 2018-present, Postdoctoral Fellow, Department of Immuno-Oncology, City of Hope, Duarte, CA

  • 2016-2017, Postdoctoral Fellow, Department of Experimental Therapeutics, City of Hope, Duarte, CA

  • 2015-2016, Postdoctoral Research Fellow, The University of Texas at Austin, Chemical Biology and Medicinal Chemistry, Austin, TX

  • 2007-2015, Graduate Research and Teaching Assistant, The University of Texas at Austin, Institute for Cellular and Molecular Biology, Austin, TX

Awards & Memberships

Memberships

  • American Association for Cancer Research (AACR)

Publications

Jose J*, Tavares CD*, Ebelt ND*, Lodi A, Edupuganti R, Xie X, Devkota AK, Kaoud TS, Van Den Berg CL, Anslyn EV, Tiziani S, Bartholomeusz C, Dalby KN. Serotonin Analogs as Inhibitors of Breast Cancer Cell Growth. *equal contribution. ACS MedChem Letters. 2017 10.1021/acsmedchemlett.7b00282
 
Ebelt ND, Edupuganti R, Kaoud TS, Dalby KN, Van Den Berg CL. A c-Jun N-terminal Kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. Oncotarget. 2017 https://doi.org/10.18632/oncotarget.20581.
 
Ebelt ND and Manuel ER. Utilizing Salmonella to Treat Solid Malignancies. J Surg Oncol. 2017 Jul;116(1):75-82. Epub 2017 Apr 18. PubMed PMID: 28420039
 
Stowers RS, Allen SC, Sanchez K, Davis CL, Ebelt ND, Van Den Berg C, Suggs LJ. Extracellular Matrix Stiffening Induces a Malignant Phenotypic Transition in Breast Epithelial Cells. Cel. Mol. Bioeng. 2016 Oct 19: DOI: 10.1007/s12195-016-0468-1. 1-10.
 
Chen WT, Ebelt ND, Stracker TH, Xhemalce B, Van Den Berg CL, Miller KM. ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion. Elife. 2015 Jun 1;4 PubMed PMID: 26030852; PubMed Central PMCID: PMC4463759.
 
Cantrell MA*, Ebelt ND*, Pfefferle AD, Perou CM, Van Den Berg CL. c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression. Oncotarget. 2015 May 20;6(14):11863-81. PubMed PMID: 25970777; PubMed Central PMCID: PMC4494910. *equal contribution
 
Ebelt ND, Cantrell MA, Van Den Berg CL. c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade. Genes Cancer. 2013 Sep;4(9-10):378-87. PubMed PMID: 24349635; PubMed Central PMCID: PMC3863335.
 
Chen P, O'Neal JF, Ebelt ND, Cantrell MA, Mitra S, Nasrazadani A, Vandenbroek TL, Heasley LE, Van Den Berg CL. Jnk2 Effects on Tumor Development, Genetic Instability and Replicative Stress in an Oncogene-Driven Mouse Mammary Tumor Model. PLoS ONE 2010 5(5): e10443
 
Gold JR, Saillant E, Ebelt ND, Lem S. Conservation Genetics of Gray Snapper (Lutjanus griseus) in U.S. Waters of the Northern Gulf of Mexico and Western Atlantic Ocean. Copeia 2009 (2):277-286